Original scientific paper
Prognostic Markers and Gene Abnormalities in Subgroups of Diffuse Large B-cell Lymphoma: Single Center Experience
Petra Korać
; Department of Pathology and Cythology, Merkur University Hospital, Zagreb, Croatia
Mara Dominis
; Department of Pathology and Cythology, Merkur University Hospital, Zagreb, Croatia
Abstract
Aim To explore the association between FOXP1, BCL2, and BCL6
gene expression in diffuse large B-cell lymphoma tumor cells and their
association with the presence of FOXP3 lymphocytes.
Methods Samples of lymph nodes from 53 patients with newly diagnosed
diffuse large B-cell lymphoma were taken at the time of the diagnosis
and immunostained for CD10, MUM1, BCL6, BCL2, FOXP1,
and FOXP3. Fluorescent in situ hybridization analysis was used for the
detection of FOXP1, BCL2, and BCL6 gene abnormalities. The χ2 test
was used for data analysis.
Results FOXP1 protein was detected in 28 cases, genetic abnormalities
involving the FOXP1 locus were found in 19 cases, and both were
present in 13 cases (χ2 =7.157; P = 0.028). FOXP3 positive cells were
detected in 37 cases. There was a significant relationship between BCL2
expression and FOXP1 genetic abnormalities (χ2 =5.858; P = 0.016)
and between BCL2 expression and BCL2 genetic abnormalities
(χ2=6.349; P = 0.012). There was also an association between BCL6
and FOXP1 genetic abnormalities (χ2 =8.497; P = 0.004).
Conclusion Association was observed between additional FOXP1
gene copies and BCL2 protein expression as well as changes on both
FOXP1 and BCL2 genes in samples of our DLBCL patients.. FOXP3
positive cells showed no association with presence of any of analyzed
proteins considered as a prognostic markers in DLBCL neither with
changes of their genes.
Keywords
DLBCL; BCL2; BCL6; FOXP1; FOXP3; expression
Hrčak ID:
29275
URI
Publication date:
15.10.2008.
Visits: 1.353 *